Biomotion
Develops an automated 3D bioprinting platform with integrated machine learning co-pilots to standardize human tissue fabrication for pharmaceutical drug screening.
- CEO / Founder
- Gregor Weisgrab
- Team Size
- 1-10
- Stage
- Early Stage
- Total Funding
- €9.2M
- Latest Round
- Grant
- Key Investors
- Austria Wirtschaftsservice (AWS); FFG (Austrian Research Promotion Agency)
Technology & Products
Key Products
ExplorerONE Bioprinting Platform; Machine Learning Bioprinting Co-pilot Software; Custom Biofabrication Workflows
Technological Advantage
Standardizes the traditionally variable bioprinting process, enabling high-throughput, reliable tissue production for drug toxicity and efficacy testing.
Differentiation
Value Proposition
Reduces drug screening variability and experimental failure rates by automating the biofabrication of human tissues using real-time ML monitoring to ensure reproducible results.
How They Differentiate
Focuses on process reliability through automated ML-driven parameter optimization, addressing the industry's primary bottleneck of bioprinting reproducibility.
Market & Competition
Target Customers
Pharmaceutical companies, contract research organizations (CROs), and biomedical research institutions.
Industry Verticals
Medical; Pharmaceutical; Biotechnology
Competitors
CELLINK; regenHU; Aspect Biosystems; Organovo
Growth & Milestones
Growth Metrics
Winner of 'Rise & Pitch' 2024 at Digital Demo Day by Rise Europe; Finalist for the Formnext Awards 2025 in the Start-up category.
Major Milestones
Founded in 2024; Launched ExplorerONE bioprinting platform; Winner of Rise & Pitch 2024; Finalist for Formnext Awards 2025
Notable Customers
UAS Technikum Wien (University of Applied Sciences Technikum Wien); TU Eindhoven (Eindhoven University of Technology)